{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:29:17Z","timestamp":1789129757633,"version":"build-2803163510"},"reference-count":15,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,15]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The survival of patients achieving a cardiac complete response in light chain amyloidosis, defined as N-terminal pro B-type natriuretic peptide \u2264350 pg\/mL or B-type natriuretic peptide \u226480 pg\/mL, was similar to that of a matched general population, with estimated 5-year survival rates of 93% and 95%, respectively.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024024623","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T16:56:56Z","timestamp":1717174616000},"page":"790-793","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":22,"title":["Patients with a cardiac complete response in AL amyloidosis have survival rates similar to those of a matched general population"],"prefix":"10.1182","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2210-2174","authenticated-orcid":false,"given":"Eli","family":"Muchtar","sequence":"first","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Geyer","sequence":"additional","affiliation":[{"name":"2Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7680-3254","authenticated-orcid":false,"given":"Giampaolo","family":"Merlini","sequence":"additional","affiliation":[{"name":"3Amyloidosis Research and Treatment Center, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy"},{"name":"4Department of Molecular Medicine, University of Pavia, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2024081515210272200_bib1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"18","key":"2024081515210272200_bib2","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2024081515210272200_bib3","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.mayocp.2021.03.012","article-title":"Treatment of AL amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement 2020 update","volume":"96","author":"Muchtar","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"14","key":"2024081515210272200_bib4","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood.2022019406","article-title":"Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial","volume":"142","author":"Gertz","year":"2023","journal-title":"Blood"},{"issue":"36","key":"2024081515210272200_bib5","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024081515210272200_bib6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ajh.23898","article-title":"Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis","volume":"90","author":"Kaufman","year":"2015","journal-title":"Am J Hematol"},{"issue":"25","key":"2024081515210272200_bib7","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood.2019000834","article-title":"A\u00a0prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib","volume":"134","author":"Manwani","year":"2019","journal-title":"Blood"},{"issue":"8","key":"2024081515210272200_bib8","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41408-020-00355-6","article-title":"Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy","volume":"10","author":"Milani","year":"2020","journal-title":"Blood Cancer J"},{"issue":"10","key":"2024081515210272200_bib9","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/s41375-018-0060-x","article-title":"Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria","volume":"32","author":"Muchtar","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"2024081515210272200_bib10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","article-title":"Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis","volume":"133","author":"Lilleness","year":"2019","journal-title":"Blood"},{"issue":"7","key":"2024081515210272200_bib11","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1200\/JCO.22.00643","article-title":"Graded cardiac response criteria for patients with systemic light chain amyloidosis","volume":"41","author":"Muchtar","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2024081515210272200_bib12","first-page":"1","article-title":"Nonparametric relative survival analysis with the R package relsurv","volume":"87","author":"Perme","year":"2018","journal-title":"J\u00a0Stat Softw"},{"key":"2024081515210272200_bib13","unstructured":"Therneau\n              TM\n            , LumleyT, AtkinsonE, CrowsonC. A package for survival analysis in R. R package version 3.5-7. 2023. Accessed 28 April 2024. https:\/\/CRAN.R-project.org\/package=survival."},{"key":"2024081515210272200_bib14","author":"Team RC R: A language and environment for statistical computing URL","year":"2021"},{"issue":"suppl 1","key":"2024081515210272200_bib15","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood-2021-149594","article-title":"Graded renal response criteria for light chain (AL) amyloidosis [abstract]","volume":"138","author":"Muchtar","year":"2021","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/7\/790\/2237722\/blood_bld-2024-024623-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/7\/790\/2237722\/blood_bld-2024-024623-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T11:21:26Z","timestamp":1723720886000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/7\/790\/516349\/Patients-with-a-cardiac-complete-response-in-AL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,15]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,8,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024024623","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,15]]}}}